ProArc Medical

ProArc Medical’s ClearRing™ is a unique prostatic reshaping device designed to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), commonly referred to as enlarged prostate.

The Product & Advantages

The ClearRing device is based on unique pre-shaped nitinol implants and a dedicated delivery system. ClearRing’s implants, in the shape of an open ring, are placed inside the enlarged prostate tissue, avoiding any long-term contact with the urine (unlike stents) and expand the obstructed area.

ClearRing is inserted into the obstructed area through a cystoscope. In a very simple, short, minimally invasive procedure (usually performed on an outpatient basis), the urologist makes a circular incision in the prostate tissue and places the implant inside it. As the incision is superficial, tissue recovery is quick, with minimal risk of adverse events.

ClearRing is positioned to be the treatment of choice for patients who have tried drugs and want to avoid surgery. It presents the market with numerous advantages:

  • Safe: It preserves the urethra and therefore minimizes risk of adverse events and avoids complications associated with surgery and other minimally invasive solutions.
  • Short: The procedure time is only a few minutes and is therefore cost effective.
  • Simple: The easy-to-learn procedure has a short learning curve.
  • Improved quality of life: ClearRing brings immediate relief of symptoms, a quick recovery, and no hospitalization.

The Team

David Nitsan, CEO: Seasoned medical device executive with extensive experience leading start-ups from idea to late stage commercialization; former CEO, JetPrep Ltd., during which time David led M&A process (2013);  MSc, MBA, BSc, all from Tel Aviv University

Trendlines’ directors: Todd Dollinger, Steve Rhodes


Stage: Business development
Founded: 2010
IP: Patents pending in United States and other countries


  • Ongoing clinical trials in Europe and Israel, with good results at 1+ year follow-up
  • Good physician feedback on speed and ease-of use of the device

Background & Market

BPH, or enlarged prostate, is a noncancerous growth of the cells within the prostate gland. A very common condition, BPH affects about 50% of men over the age of 50 and 80% over the age of 80. Symptoms include a weak or slow urinary stream, a feeling of incomplete bladder emptying, delay in starting urination, frequent urination, and urinary urgency.

Current treatment options have numerous shortcomings:

  • Medical therapy, a long-term and expensive option, is associated with side effects such as asthenia (loss of strength), dizziness, headaches, and sexual dysfunction.
  • The surgical gold standard, Transurethral Resection of the Prostate (TURP), is associated with a 20% rate of perioperative morbidity, need for general anesthesia, routine catheterization, and long-term complications.
  • New minimally invasive solutions that use heat-based technologies to ablate the prostate tissue can induce thermal injury and subsequent tissue inflammation that results in irritative voiding symptoms, routine catheterization, and a 20% to 25% risk of acute urinary retention.

Despite the options available, the market continues to seek innovative treatments that will reduce adverse events, decrease hospitalization stay, and improve quality of life.

Each year, an estimated 38 million men in the United States and EU with BPH become symptomatic and seek medical attention; 25% have debilitating conditions that require active treatment. The caseload is only expected to rise with the increase in the aging population. An estimated 1.5 million BPH procedures will be performed in the United States and EU in 2012, resulting in a $1.5 billion market opportunity for ProArc Medical.

Now Funding

Now Funding Medical iconProArc is now funding.

See the presentation (PDF). Send more information about ProArc.


David Nitsan, CEO

ProArc logo

Font Resize